Jonas Ghouse

Jonas Ghouse, MD, PhD

Exploring genetic determinants for effectiveness and safety of common cardiovascular agents – genome-wide association studies of people treated with statin and renin-angiontensin-system inhibitors

Cardiovascular diseases are reaching pandemic proportions and at present accounts for almost 18 million deaths yearly. Although effective drugs that target risk factors such as high cholesterol and blood pressure exist, there is large variation in the way patients respond to a given therapy. In other words, some may experience an effective drug response, some may have no therapeutic effect, whereas others only develop side effects. These variations have been ascribed to differences in genetic profile. By integrating genetic data with health care data, we aim to identify genes that may play a role in drug response and risk of developing side effects. We believe that genetic information obtained from these types of studies can lead to new diagnostic procedures of testing for genetic markers. This will aid the physician in selecting the right drug for the right person, thus avoiding numerous follow-up visits to change and adjust prescriptions and improving drug safety and adherence.


Basic mentor: Morten Salling Olesen, PhD, Associate Professor, Department of Biomedical Sciences, University of Copenhagen

Clinical mentor:  Henning Bundgaard, MD, DMSc, Professor of Cardiology, Senior Consultant (Chief Physician), Department of Cardiology, Rigshospitalet